MAP2K7 and melanoma: However, a first clinical test of this concept demonstrated that continuous dosing was superior to intermittent dosing of combination BRAF/MEK inhibitor therapy for advanced melanoma [60], questioning whether this concept from mouse models may translate to the human disease setting.